Global Divalproex sodium market to reach USD XX billion by 2027Global Divalproex sodium market is valued at approximately USD XX million in 2020 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2021-2027. Divalproex sodium is an anti-epileptic medicine licensed by the Food and Drug Administration (FDA) for the treatment of migraine headaches, bipolar disorder manic episodes, and some types of seizures. Divalproex sodium is used to treat epilepsy because of its anticonvulsant effects. The growing number of people suffering from epilepsy and migraine headaches around the world is predicted to enhance demand for divalproex sodium dramatically. According to the World Health Organization's 2018 important statistics, epilepsy affects roughly 50 million people worldwide, making it one of the most common neurological diseases, and approximately 80% of those affected live in low and middle-income countries. Similarly, according to a study published in the Journal of Global Health in 2017, lifetime epilepsy prevalence in the Chinese population was 1.99 percent in 1990 and 7.15 percent in 2015. The market for divalproex sodium is growing because to the rising frequency of bipolar illnesses around the world. According to a 2017 study by the National Alliance on Mental Illness, the typical age of beginning of bipolar disorder is around 25, but it can also arise in adolescence or, less commonly, childhood. Bipolar disorder affects both men and women equally, with roughly 2.8 percent of the population in the United States being diagnosed, and nearly 83 percent of cases being categorized as severe. However, the use of divalproex sodium tablet and other known adverse reactions such as neurobehavioral adverse effects, birth defects, and suicidal behavior may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global Divalproex sodium market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World (ROW). North America is the leading region across the world in terms of market share due to increased government initiatives and rising research and development for the introduction of new product in the region. Whereas North America is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to increased prevalence of epilepsy and head migraine among the population across the region.

Major market player included in this report are:

AbbVie Inc.
Zydus Cadila
Aurobindo Pharma
Dr. Reddy's Laboratories Ltd.
Lupin Pharmaceuticals, Inc.
Orchid Pharma Ltd
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Abbott Laboratories
Mylan N.V.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Tablet
Capsule
Syrup
By Application:
Epilepsy and Migraine Headaches
Manic-Depressive Illness
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018-19
Base year - 2019-2020
Forecast period - 2021 to 2027.

Target Audience of the Global Divalproex sodium market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors